Lab Automation Market Analysis & Forecast: 2026-2033
The lab automation market size is anticipated to grow at a CAGR of 7.2% with USD 8.37 Bn in 2026 and is expected to reach USD 13.62 Bn in 2033. The primary drivers are largely defined by increasing diagnostic workloads, as CDC notes nearly 14 billion laboratory tests are conducted annually and 70% of medical decisions depend on laboratory results. Some of the other drivers include rising labor costs, shortage of skilled professionals, increased R&D spending, and the need for standardized workflows, particularly in genomics and clinical testing
On the basis of product, the liquid handling products is projected to account for the largest lab automation market share of 38.3% in 2026. The segment is gaining the highest share because liquid handling is required at the most repetitive and error-sensitive stage of laboratory workflows, including sample preparation, reagent dispensing, assay setup, serial dilution, PCR preparation, ELISA workflows, microplate processing, and high-throughput screening.
The demand is especially strong in clinical diagnostics, pharmaceutical research, biotechnology, academic labs, and CROs. This is because laboratories need faster turnaround time, lower manual variation, and higher reproducibility. The regulatory alignment is also contributing to the adoption. For example, in May 2025, the FDA recognized multiple CLSI laboratory automation standards covering specimen container barcodes, specimen carriers, instrument communication, specimen identification data, and IT security, which strengthens interoperability as well as confidence in automated workflows.
In July 2025, These factors directly justify why liquid handling products continue to hold the largest share in the lab automation market.
To learn more about this report, Request Free Sample
Biopharmaceuticals and pharmaceuticals lead with a major 42.50% share in 2026. These laboratories depend heavily on automated workflows for drug discovery, assay development, sample preparation, stability testing, batch release testing, quality control, and regulatory documentation.
The segment is supported by strong R&D intensity, as the pharmaceutical industry spent USD 129 billion on R&D in 2022, while active product-indication combinations in global development more than doubled between 2013 and 2023, reaching 41,370. The data from OECD also shows that retail pharmaceutical expenditure averaged USD 766 per capita in 2023. The prescription medicines accounted for more than 75% of spending in most countries, thereby reflecting high regulated medicine volumes that require testing and compliance workflows.
Chronic therapy consumption further supports testing demand, with antihypertensive medicine use rising around 6% and lipid-modifying agents rising almost 65% during 2013–2023. A relevant product update is Beckman Coulter’s Biomek i-Series. The family added the Biomek i3 Benchtop Liquid Handler in Fall 2025, thus strengthening automation adoption in pharma and biopharma labs.
The technological advancements are revolutionizing the U.S. lab automation market. This is because the clinical laboratories are increasingly adopting faster, standardized, and more efficient workflows. Technologies like automated liquid handling, barcoding, specimen tracking, robotic sample preparation, digital data capture, and AI-driven interpretation are crucial for reducing errors and increasing efficiency in high-volume diagnostic environments.
In 2025, the FDA’s recognition of CLSI laboratory automation standards, which covers specimen carriers, barcodes, system operations, and specimen identification, will further facilitate the development of interoperable automated platforms. The FDA-approved Oncomine Dx Express Test showcases the power of automation in laboratory workflows, thereby underscoring how automated library preparation, sequencing, analysis, and reporting can be done with only 20 minutes of hands-on time.
In addition, the 2025 reversal of the FDA’s LDT rule will continue to focus on CLIA-based validation, quality control, and scalable laboratory workflow compliance, thereby ensuring that automated clinical testing environments in the U.S. adhere to high standards.
AI-powered end-to-end lab automation platforms are emerging as a major breakthrough as laboratories move beyond standalone instruments toward fully connected digital workflows. These platforms now support the complete laboratory cycle like sample intake, specimen tracking, testing, data analysis, reporting, quality control, and compliance management. The regulatory momentum is also strengthening this transition. For instance, in May 2025, the U.S. FDA completed its first AI-assisted scientific review pilot and announced plans to scale AI use in all centers by June 2025. Also, in June 2025, the FDA launched Elsa, an AI tool mainly designed to speed up clinical protocol reviews, shorten scientific evaluations, summarize adverse events, compare labels, and support database development.
The foundation for automated laboratory operations is further strengthened by the FDA-recognized CLSI standards which covers laboratory barcodes, specimen carriers, system operations, instrument communication, LIS data transfer, autoverification, remote access, specimen data content, and IT security. One of the product developments is LabVantage’s CORTEX, launched in March 2026. The platform integrates AI, analytics, automation, agentic AI, cloud-native workflows, IoT connectivity, digital twins, predictive maintenance, automated compliance monitoring, and workflow assistance into the LIMS environment.
|
Current Event |
Description and its Impact |
|
FDA Recognition of Laboratory Automation Standards (2025) |
|
|
FDA Recognition of Laboratory Automation Standards (2025) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 37.60% of the market share in 2026. The region’s growth is owing to the strong base of certified clinical laboratories, high diagnostic test volumes, advanced biopharma R&D, and faster adoption of robotics, liquid handlers, automated sample preparation, and laboratory information systems.
In the U.S., CMS states that CLIA covers approximately 320,000 laboratory entities, creating a large installed base where automation is required to improve throughput, quality control, compliance documentation, and turnaround time. The CDC’s 2025 data-modernization update also highlights expanded access to clinical laboratory data across more than 200 reportable conditions, supporting demand for connected and automated lab workflows.
One key product development was Ginkgo Bioworks’ official launch of Ginkgo Cloud Lab in March 2026, a new platform that enables researchers to seamlessly shift their benchwork to Ginkgo’s autonomous lab infrastructure through a web browser.
Asia Pacific is expected to witness strong growth in lab automation market over the forecast period. The region’s growth is owing to rapid expansion of public diagnostic infrastructure, higher infectious-disease surveillance needs, and rising pressure on clinical laboratories to process samples faster with fewer manual errors.
In India, PM-ABHIM has approved 744 Integrated Public Health Labs and 2,151 Block Public Health Units, while the program targets one integrated lab in each of 730 districts, directly increasing demand for automated biochemistry, hematology, microbiology, molecular, and sample-management systems.
One such product development is Roche’s new cobas® 6800/8800 systems version 2.0 and software version 2.0.1 in December 2025. The upgraded systems are designed to improve laboratory efficiency by optimizing resource use, minimizing downtime, consolidating testing menus, and increasing overall throughput.
The demand for lab automation in the United States is being driven by rising laboratory workloads and the need for faster, high‑throughput testing across clinical, research, and public health environments. According to the American Clinical Laboratory Association’s official data, more than, thereby underscoring the scale of workload that automation can help manage with improved efficiency and accuracy.
At the regulatory end, a major FDA action to roll back enhanced oversight for lab‑developed diagnostic tests (LDTs) was finalized in 2025, thus reducing compliance burdens that previously slowed diagnostic innovation and indirectly supporting broader automation adoption.
In product developments, Clarapath launched its FDA
China’s lab automation market is shifting from standalone instruments to integrated, high-throughput workflows as hospitals, disease control laboratories, genomic centers, and biopharma labs manage rising sample volumes.
Official 2025 statistics show China had 1.107 million medical and health institutions, including 38,000 hospitals, 3,478 disease control and prevention centers, 13.40 million medical technical personnel, 10.58 billion medical visits, and 300 million hospital discharges, creating strong demand for faster testing, sample tracking, and reduced manual error.
At the product level, Shenzhen-based MGI Tech expanded its automation portfolio in January 2024 across sample pre-treatment, automated sample preparation, and integrated testing, supporting automated nucleic-acid extraction, sequencing library preparation, and multi-omics diagnostics.
Some of the major key players in lab automation market are Tecan Trading AG, PerkinElmer Inc., Danaher, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Inc., Hamilton Company, COPAN Diagnostics Inc., Abbott, Merck KGaA, F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited, UiPath, and Porvair Sciences, SPT Labtech Ltd, Endress+Hauser Group Services AG, Automata, accroma, Molecular Devices, LLC, Beckman Coulter, Inc., BD, Reshape Biotech, Peak Analysis & Automation.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.37 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.2% | 2033 Value Projection: | USD 13.62 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Tecan Trading AG, PerkinElmer Inc., Danaher, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Inc., Hamilton Company, COPAN Diagnostics Inc., Abbott, Merck KGaA, F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited, UiPath, and Porvair Sciences, SPT Labtech Ltd, Endress+Hauser Group Services AG, Automata, accroma, Molecular Devices, LLC, Beckman Coulter, Inc., BD, Reshape Biotech, Peak Analysis & Automation |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
